Cargando…

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cottini, Francesca, Huang, Ying, Williams, Nita, Bumma, Naresh, Khan, Abdullah M., Chaudhry, Maria, Devarakonda, Srinivas, Efebera, Yvonne A., Benson, Don M., Rosko, Ashley E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917249/ https://www.ncbi.nlm.nih.gov/pubmed/33659205 http://dx.doi.org/10.3389/fonc.2020.575168

Ejemplares similares

Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
por: Nunnelee, Jordan, et al.
Publicado: (2022)

Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
por: Nunnelee, Jordan, et al.
Publicado: (2022)

Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma
por: Khan, Abdullah M., et al.
Publicado: (2023)

Racial differences as predictors of outcomes in young patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2022)

Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2023)

Daratumumab in Patients With Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
por: Almaani, Salem, et al.
Publicado: (2021)

Role of Stem Cell Transplantation in Multiple Myeloma
por: Devarakonda, Srinivas, et al.
Publicado: (2021)

AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes
por: Ozga, Michael, et al.
Publicado: (2020)

AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival
por: Ozga, Michael, et al.
Publicado: (2020)

Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
por: Sharma, Nidhi, et al.
Publicado: (2021)

Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant
por: Sigmund, Audrey M., et al.
Publicado: (2022)

Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation
por: Sharma, Nidhi, et al.
Publicado: (2021)

Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma
por: Ozga, Michael, et al.
Publicado: (2023)

Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
por: Braunstein, Zachary, et al.
Publicado: (2022)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
por: Sborov, Douglas W., et al.
Publicado: (2022)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone
por: Alkharabsheh, Omar, et al.
Publicado: (2023)

Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift
por: Wall, Sarah A., et al.
Publicado: (2022)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
por: Fucci, Ludovica, et al.
Publicado: (2022)

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023)

Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States
por: Fonseca, Rafael, et al.
Publicado: (2023)

P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS
por: Miguel, Enrique Maria Ocio San, et al.
Publicado: (2023)

Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
por: Kalis, Joseph A.
Publicado: (2017)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
por: Zajec, Marina, et al.
Publicado: (2020)

Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
por: Agrawal, Soma, et al.
Publicado: (2020)

PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.
por: Fonseca, R., et al.
Publicado: (2022)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018)

New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim, Cian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bro5auu38t1f6ef3tvghkb3v00